Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) announced that its investigational LCA5 gene therapy, OPGx-LCA5, was accepted into the FDA's Rare Disease Evidence Principles (RDEP) program on May 4, 2026. RDEP acceptance enables early FDA collaboration on regulatory strategy, trial design, evidence generation, and evaluation frameworks for ultra-rare diseases.
The program covers approaches to demonstrating clinical benefit in small populations and may allow a single adequate and well-controlled study supported by confirmatory evidence as part of a potential approval pathway.
Positive
- FDA RDEP acceptance for OPGx-LCA5
- Aligns with existing RMAT designation
- Early FDA collaboration on trial design
- Potential single-study approval pathway with confirmatory evidence
Negative
- OPGx-LCA5 remains investigational
- Targets an ultra-rare population (<1,000 US patients)
- No approved therapies currently exist for LCA5
News Market Reaction – IRD
In the May 5 session, IRD declined 0.38%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Conference participation | Positive | -2.1% | Announced multiple ophthalmology and gene‑therapy conference presentations in May 2026. |
| Apr 10 | Conference data | Positive | -2.5% | Planned three ASCRS abstracts including full Phase 3 VEGA‑3 results in presbyopia. |
| Apr 06 | Strategic financing | Positive | +1.3% | Secured up to $155M largely non‑dilutive capital and extended cash runway to 2029. |
| Mar 24 | Industry recognition | Positive | -1.7% | Named to Fast Company’s World’s Most Innovative Companies 2026 in Biotech. |
| Mar 10 | Earnings & update | Positive | +1.7% | Reported 2025 results with $45.1M cash and funding into H1 2028 plus clinical progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive in tone, but price reactions have been mixed, with more instances of divergence than alignment.
Over the last few months, Opus Genetics reported multiple corporate and clinical milestones. Financing with Oberland Capital for up to $155 million and 2025 results highlighted extended runway into 2028–2029 and progress in OPGx‑LCA5 and OPGx‑BEST1. Recognition on Fast Company’s 2026 innovators list and several conference presentation announcements often saw muted or negative next‑day price moves, underscoring that good news has not always translated into immediate upside. Today’s FDA RDEP acceptance adds to this regulatory and development momentum.
Key Terms
gene therapy medical
Leber congenital amaurosis type 5 medical
Rare Disease Evidence Principles (RDEP) regulatory
RMAT designation regulatory
Phase 3 medical
adequate and well-controlled study regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration’s (FDA) Rare Disease Evidence Principles (RDEP) program.
OPGx-LCA5 is a potential gene therapy for Leber congenital amaurosis type 5 (LCA5), a rare inherited retinal disease caused by mutations in the LCA5 gene. The condition leads to early-onset, progressive vision loss and often results in severe visual impairment or blindness in childhood. There are currently no approved therapies specifically targeting LCA5.
RDEP is a new FDA initiative intended to support the development of therapies for ultra-rare genetic diseases typically affecting fewer than 1,000 patients in the U.S. The program enables early and ongoing collaboration between the FDA and sponsors to align on regulatory strategy, clinical trial design, and innovative approaches to generating evidence needed to support potential approval.
“RDEP eligibility represents an important element of our regulatory strategy as we seek alignment with the FDA on our pivotal Phase 3 program for OPGx-LCA5,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “Given the rarity and severity of this disease, early engagement with the FDA alongside our RMAT designation will help inform a more efficient and streamlined development pathway. We look forward to collaborating with the FDA as we pursue a potential treatment option for patients affected by this devastating inherited retinal disease.”
As part of the RDEP program, the FDA will work closely with Opus Genetics to guide the ongoing development of OPGx-LCA5, including considerations for clinical trial design, approaches to generating efficacy in a small patient population, and strategies to support demonstration of clinical benefit. The program also provides a framework for evaluating substantial evidence of effectiveness, including the potential use of a single adequate and well-controlled study supported by confirmatory evidence.
About OPGx-LCA5
OPGx-LCA5 is designed to address a form of Leber congenital amaurosis (LCA) due to biallelic mutations in the LCA5 gene (LCA5), which encodes the lebercilin protein. LCA5-associated inherited retinal disease is an early-onset severe inherited retinal dystrophy. Studies in patients with this mutation have reported evidence for the dissociation of retinal architecture and visual function in this disease, suggesting an opportunity for therapeutic intervention through gene augmentation. OPGx-LCA5 uses an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to the outer retina. OPGx-LCA5 is currently being evaluated in a Phase 1/2 clinical trial at the University of Pennsylvania. Data from pediatric participants demonstrated large gains in cone-mediated vision, and the therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities. The adult cohort showed durable improvements in cone sensitivity and visual function out to 18 months. OPGx-LCA5 has also received Rare Pediatric Disease, Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. Opus Genetics is also advancing a small-molecule therapy, Phentolamine Ophthalmic Solution
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to the clinical development, clinical results, preclinical data, and future plans for OPGx-LCA5 and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
